NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Atara Biotherapeutics, Inc.’s ATRA share price has surged by 12.53%, which has investors questioning if this is right time to ...

Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Atara Biotherapeutics will be completing its third large-scale layoff in four years after the biotech company announced plans to shed 50% of its workforce by the end of June. Atara, a Thousand ...

Equities researchers at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Atara ...

HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, ...

Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood ...

H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to InvestingPro data, ...

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...